Arcus Biosciences, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2017 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Arcus Biosciences, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2017 to Q4 2024.
  • Arcus Biosciences, Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was -$94M, a 16% decline year-over-year.
  • Arcus Biosciences, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was -$283M, a 7.82% increase year-over-year.
  • Arcus Biosciences, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$283M, a 7.82% increase from 2023.
  • Arcus Biosciences, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$307M, a 15% decline from 2022.
  • Arcus Biosciences, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$267M, a 604% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 -$283M -$94M -$13M -16% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-25
Q3 2024 -$270M -$92M -$21M -29.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 -$249M -$93M -$18M -24% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-06
Q1 2024 -$231M -$4M +$76M +95% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-06
Q4 2023 -$307M -$81M -$14M -20.9% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-25
Q3 2023 -$293M -$71M -$6M -9.23% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 -$287M -$75M -$8M -11.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-06
Q1 2023 -$279M -$80M -$12M -17.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-06
Q4 2022 -$267M -$67M -$347M -124% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-25
Q3 2022 $79.5M -$65M +$13M +16.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $66.6M -$67M +$8.97M +11.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-07
Q1 2022 $57.6M -$68M +$4.59M +6.33% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-07
Q4 2021 $53M $280M +$331M Oct 1, 2021 Dec 31, 2021 10-K 2024-02-21
Q3 2021 -$278M -$78M -$79.8M -4380% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 -$199M -$76M -$30.9M -68.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-02
Q1 2021 -$168M -$72.6M -$44.8M -162% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-02
Q4 2020 -$123M -$51.9M -$35.3M -212% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-25
Q3 2020 -$87.6M $1.82M +$24.2M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$112M -$45.1M -$17M -60.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-08
Q1 2020 -$94.8M -$27.8M -$10.1M -57.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-08
Q4 2019 -$84.7M -$16.6M -$4.3M -35% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 -$80.4M -$22.4M -$11.5M -107% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-25
Q2 2019 -$68.9M -$28.1M -$14.6M -108% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-25
Q1 2019 -$54.3M -$17.7M -$4.72M -36.4% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-25
Q4 2018 -$49.6M -$12.3M +$915K +6.93% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-05
Q3 2018 -$50.5M -$10.8M +$12.3M +53.2% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-05
Q2 2018 -$62.8M -$13.5M -$3.98M -41.7% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-05
Q1 2018 -$58.8M -$13M -$5.75M -79.9% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-05
Q4 2017 -$53.1M -$13.2M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-05
Q3 2017 -$23.1M Jul 1, 2017 Sep 30, 2017 10-K 2019-03-05
Q2 2017 -$9.55M Apr 1, 2017 Jun 30, 2017 10-K 2019-03-05
Q1 2017 -$7.2M Jan 1, 2017 Mar 31, 2017 10-K 2019-03-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.